| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President And CEO | EVP And General Counsel
1 company
Masoud Maher serves as a President And CEO at MXCT. Across recent SEC filings that breaks down to 3 buys and 3 sells.
Historically, Masoud Maher's trades have earned a middling insider score of 54/100 across 6 rated trades. Over a 12-month horizon, 60.0% of those trades were profitable, with an average 12-month return of +5.1%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 13, 2025 | MXCT Maxcyte, Inc. | President And CEO | Buy | 75,000 | $1.37 | $102,915.00 | +75.0% | +12.3% | +0.7% | |
| Jun 10, 2024 | MXCT Maxcyte, Inc. | President And CEO | Buy | 100,000 | $4.89 | $489,065.51 | New | -22.8% | -53.4% | |
| Nov 16, 2021 | MXCT Maxcyte, Inc. | EVP And General Counsel | Sale+OE | 75,000 | $12.31 | $923,376.04 | -100% | -49.5% | -48.2% |